Document is current

Any future updates will be listed below

Migräneprophylaxe: Eptinezumab punktet mit Dreimonatsgabe

Crossref DOI link: https://doi.org/10.1007/s00940-024-4735-2

Published Online: 2024-05-02

Published Print: 2024-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark